Pasithea Therapeutics (KTTAW) Competitors $0.03 +0.01 (+71.79%) Closing price 08/4/2025 04:00 AM EasternExtended Trading$0.03 0.00 (0.00%) As of 08/4/2025 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock KTTAW vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, and CALAShould you be buying Pasithea Therapeutics stock or one of its competitors? The main competitors of Pasithea Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Calithera Biosciences (CALA). These companies are all part of the "pharmaceutical products" industry. Pasithea Therapeutics vs. Its Competitors 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Calithera Biosciences Pasithea Therapeutics (NASDAQ:KTTAW) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment. Which has preferable valuation and earnings, KTTAW or ATNFW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPasithea TherapeuticsN/AN/AN/AN/AN/A180 Life SciencesN/AN/AN/AN/AN/A Is KTTAW or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets Pasithea TherapeuticsN/A N/A N/A 180 Life Sciences N/A N/A N/A Does the media prefer KTTAW or ATNFW? In the previous week, 180 Life Sciences had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 1 mentions for 180 Life Sciences and 0 mentions for Pasithea Therapeutics. 180 Life Sciences' average media sentiment score of 0.48 beat Pasithea Therapeutics' score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment Pasithea Therapeutics Neutral 180 Life Sciences Neutral Summary180 Life Sciences beats Pasithea Therapeutics on 2 of the 2 factors compared between the two stocks. Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTAW and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KTTAW vs. The Competition Export to ExcelMetricPasithea TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$134.69M$5.51B$9.35BDividend YieldN/A3.74%4.74%4.15%P/E RatioN/A3.7629.1424.41Price / SalesN/A4,422.29435.00101.03Price / CashN/A13.1924.4827.20Price / BookN/A39.418.525.77Net IncomeN/A-$90.99M$3.24B$264.99M7 Day PerformanceN/A-1.70%0.65%-0.68%1 Month PerformanceN/A3.80%7.97%7.08%1 Year PerformanceN/A182.92%30.98%23.80% Pasithea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KTTAWPasithea TherapeuticsN/A$0.03+71.8%N/A+49.7%$0.00N/A0.003Gap UpATNFW180 Life SciencesN/A$0.01+6.1%N/A+6.0%$0.00N/A0.007Gap UpLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.00flatN/A-79.1%$0.00N/A0.002AIMDWAinosN/A$0.12flatN/A+71.4%$0.00$106.21K0.0040Positive NewsALVOWAlvotechN/A$1.60-17.5%N/A-41.2%$0.00$585.60M0.004Positive NewsACABWAtlantic Coastal Acquisition Corp. IIN/A$0.05-0.6%N/A-24.8%$0.00N/A0.0015High Trading VolumeBFRIWBiofronteraN/A$0.15-16.7%N/AN/A$0.00$38.00M0.0070Positive NewsGap UpBTMDWbioteN/A$0.01-32.2%N/AN/A$0.00$199.38M0.00N/ABCTXWBriaCell TherapeuticsN/A$0.04-10.0%N/A-77.1%$0.00N/A0.008Positive NewsShort Interest ↑Gap UpCALACalithera Biosciences2.0819 of 5 starsN/AN/AN/A$0.00N/A0.0060 Related Companies and Tools Related Companies 180 Life Sciences Alternatives 4D pharma Alternatives Aesther Healthcare Acquisition Alternatives Ainos Alternatives Alvotech Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Biofrontera Alternatives biote Alternatives BriaCell Therapeutics Alternatives Calithera Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KTTAW) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KTTAW Stock Alerts